New Recipe Test
sdfgsdfg
asdgfasdf
asdfasdf
asdfasdf
asdfasdf
asdfasdfas
asdfasdfasdf
asdfasdf
asdfasdfasdf
Do not drink this; You will die.
News
Page of ( Articles)
Articles beyond this point are archived and can be individually purchased.
-
-
Recipe Example
MedAdvisor is teaming up with Bupa to launch its popular pharmacy app to the health fund's 4 million members and the wider community. MedAdvisor keeps pharmacists and patients permanently... -
PBAC
This is how you use Sqloo echo "Hello World"; -
Regrets over PBPA?
Industry might be having second thoughts over the abolition of the Pharmaceutical Benefits Pricing Authority. While surprised at Health Minister Peter Dutton's decision in March to abolish the... -
Still no clarity on MSAC
Still no word from Health Minister Peter Dutton on the composition of the Medical Services Advisory Committee (MSAC). The terms of all MSAC members expired at the end of June - all positions are... -
Set responses only
Companies have described as "petty" a decision by the Department of Health to limit their formal responses to rejections or deferrals by the Pharmaceutical Benefits Advisory Committee... -
New hope for cancer sufferers
Researchers at the Children’s Medical Research Institute (CMRI) have discovered a key process they believe could lead to new treatments for some of the deadliest cancers. Telomeres are a type of... -
Continuing shift away from the PBS
The latest statistics from Medicare Australia for July confirm the continuing decline in the non-concessional General PBS category. General patients currently pay a PBS patient co-payment of... -
New resource for patients at risk of stroke
Bristol-Myers Squibb and Pfizer have teamed up with the National Stroke Foundation to produce a new resource for patients living with atrial fibrillation. The 'Living with atrial fibrillation'... -
Follow-up analysis from MAESTrO
In a follow-up analysis, MAESTrO Database has provided an additional breakdown of outcomes from the July meeting of the Pharmaceutical Benefits Advisory Committee. As reported by PharmaDispatch... -
Debate ignores private market, but consumers don't
The non-PBS private market remains the best option for many consumers, but is largely disregarded in policy discussions regarding the PBS. An updated PharmaDispatch analysis of 10 commonly... -
Now it's getting embarrassing
The Grattan Institute's updated submission to the Senate inquiry on the proposed increase in PBS patient co-payments only confirms the profound flaws in its original analysis. The Grattan...
Page of ( Articles)
There are no results for your search.